Purpose: Many outcomes derived from electronic health records (EHR) not only are imperfect but also may suffer from exposure-dependent differential misclassification due to variability in the quality and availability of EHR data across exposure groups.
| INTRODUCTION
Electronic health records (EHR) have become an important data source for investigating adverse outcomes associated with pharmacologic exposures. However, EHR-derived data are imperfect, and many recent studies have drawn attention to multiple challenges of working with this data source. [1] [2] [3] One challenge of working with EHR data is the lack of gold-standard information on patient outcomes. It is well known that This work has not been posted or presented previously. Research reported in this paper was supported by the National Institutes of Health under award numbers R01CA120562, R01CA09377, R01LM012607, R01AI130460, and R21CA143242 and the American Cancer Society under award number CRTG-03-024-01-CCE.
nondifferential outcome misclassification, in which sensitivity and specificity of the surrogate outcome are unrelated to the true exposure status, tends to bias results towards the null. 4 However, if misclassification is differential, bias can be towards or away from the null. 5, 6 Differential misclassification of outcomes with respect to exposure status may be common in EHR-based studies investigating pharmacologic exposures because patients receiving treatments of interest may access the health care system more frequently, leading to richer EHR data and possibly more sensitive and/or less specific outcome ascertainment for these patients. 7 EHR-based studies are frequently used for hypothesis generation and identification of novel risk factors. A key concern for findings from such studies is lack of reproducibility. [8] [9] [10] [11] For EHR-based discovery, outcome misclassification is a key contributor to irreproducibility.
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Using data from the eMERGE study, we previously quantified the loss of power attributable to outcome misclassification. 13 However, spurious associations induced by outcome misclassification are also an important contributor to lack of reproducibility.
We have previously developed and validated an EHR-based algorithm for identifying second breast cancers in women with a personal history of breast cancer. 14, 15 An EHR-derived second breast cancer measure can be paired with pharmacologic exposures derived from prescription or drug dispensing databases to identify medications that may increase or decrease the risk of a second breast cancer. Using the previously developed EHR-based algorithm, we conducted statistical simulation studies to investigate bias in association parameter estimates due to differential outcome misclassification. We found that, when misclassification of second breast cancers was nondifferential, parameter estimates were only minimally biased. However, under differential misclassification bias became relatively severe. 16 The objective of this paper was to extend our previous investigation on bias due to differential misclassification in EHR-derived out- records and extracted from a tumor registry to provide gold-standard outcome information. In addition, a "high specificity algorithm" for second breast cancer events 15 was applied to structured EHR data to obtain an algorithm-derived second breast cancer indicator. Estimated sensitivity and specificity for this algorithm were 89% and 99%, respectively. 15 The BRAVA study was reviewed and approved by the Kaiser Permanente Washington Institutional Review Board.
| Simulation study
The objective of simulation studies was to estimate the frequency of false-positive findings (ie, type I errors) that is induced when a surrogate outcome subject to differential misclassification is used rather than the gold-standard outcome. Simulations used BRAVA data on second breast cancers and patient characteristics combined with a simulated, hypothetical medication exposure that does not affect second breast cancer risk. We used data from BRAVA on a binary goldstandard outcome (second breast cancers, D), a binary surrogate outcome (algorithm-derived second breast cancers, S), and patient risk factors (X). We then simulated a binary exposure (E), which was independent of true second breast cancer status but associated with the sensitivity and specificity of the surrogate outcome. E represents a novel exposure suspected of increasing second breast cancer risk such as a medication. In simulation studies, we used values for S and D observed in the BRAVA data and simulated E from a Bernoulli distribution with probability given by the following equation. Specifically, under
KEY POINTS
• Exposure-dependent differential outcome misclassification may occur in pharmacoepidemiologic studies using EHR-derived outcomes in which exposures are related to the frequency or intensity of interaction with the health care system.
• Differential outcome misclassification leads to substantial inflation of the type I error rate.
• Type I error inflation due to differential outcome misclassification is particularly severe when outcome specificity differs between exposed and unexposed individuals.
• Exposure-stratified estimates of outcome operating characteristics and misclassification adjusted analytic methods are needed to reduce the risk of spurious findings.
independence of outcome and exposure, the probability of E = 1 conditional on S and D is given by
where j = 0, 1.
We set the marginal prevalence of exposure, P(E = 1), to 0.2. We fixed α 10 , sensitivity in the unexposed group, at 0.85 and α 00 , 1-specificity in the unexposed group, at 0.1. We then varied sensitivity and 1-specificity in the exposed group, α 11 and α 01 ,across a range of values. We repeated the process of simulating the exposure variable E 1000 times for each combination of α 11 and α 01 .
The target of inference was the odds ratio (OR) for the association between D and E, adjusted for patient risk factors X. However, we assume that in the context of an EHR-based study, only information on S is available rather than D and therefore estimate the association between S and E adjusted for X. Although E was simulated independent of X, we adjusted for X in all analyses to mirror common practice in pharmacoepidemiologic studies of adjusting for variables known to be strongly associated with the outcome of interest. In settings where the association of these factors with the exposure of interest is uncertain, they are typically included in regression models to address the possibility of confounding.
Additional simulation studies using simulated true and surrogate disease outcomes, as opposed to observed values in the BRAVA cohort, in addition to simulated exposures allowed us to investigate a broad range of values for outcome prevalence as well as sensitivity and specificity in the unexposed group. As results were similar, we present only analyses using outcomes from BRAVA data combined with simulated exposures. The additional simulations are available in the Supporting information.
| Statistical analysis
Using BRAVA data on S and X combined with simulated exposure data (E), we estimated the association between E and S using multivariable logistic regression. Logistic regression models adjusted for simulated exposure, E, and variables in X: age (continuous), year at diagnosis (categorical), primary breast cancer stage (categorical), and estrogen and progesterone receptor (ER and PR) status (categorical). For each model, we used the P value based on the Wald statistic for the OR associated with E to determine whether to accept or reject the null hypothesis, using a threshold for statistical significance of 0.05. For each combination of α 01 and α 11 , we computed the proportion of simulations in which we rejected the null hypothesis. Since, in all settings, E was simulated to be independent of D, this proportion estimated the type I error. Using a significance threshold of 0.05, 5% of simulations would result in rejected null hypotheses if there were no type I error inflation.
| RESULTS
Our simulations used data on 3152 women included in the BRAVA study (Table 1) . In this sample, 407 patients were observed to experience a second breast cancer during study follow-up based on tumor registry and manual abstraction of patients' medical records. Thus, the prevalence of second breast cancer events in the BRAVA dataset, P(D = 1), in this cohort was 0.129. Adjusted logistic regression models for the association between a simulated, independent exposure, and second breast cancer status exhibited substantial inflation of the type I error rate as both sensitivity and specificity of the surrogate second breast cancer measure for exposed individuals deviated from their values in unexposed individuals (Figure 1) . When sensitivity and specificity were the same in exposed and unexposed individuals (nondifferential misclassification), type I error was 0.05. Holding specificity equal in exposed and unexposed individuals, when sensitivity was 10% higher in exposed individuals compared with unexposed (ie, 0.95 vs 0.85) the type I error rate increased to 17%. Similarly, holding sensitivity equal between the two groups, a 10% decrease in specificity between exposed and unexposed individuals (ie, 0.80 vs 0.90) resulted in a type I error rate of 36%.
| DISCUSSION
Our analysis found that, in the context of an investigation of second breast cancers using EHR-derived outcomes subject to misclassification, type I error was substantially inflated above the nominal level when outcome misclassification was differential with respect to exposure. Even for an outcome with marginally good sensitivity and specificity, differences in accuracy between exposed and unexposed individuals frequently induced a spurious association between outcome and exposure. Results were particularly sensitive to differential specificity, with type I error increasing to very high levels for even small differences in specificity between exposed and unexposed individuals.
Differential misclassification is likely to be common in many settings using health care data, particularly those investigating medication exposures. Because classification accuracy is dependent on the intensity and type of interaction a patient has with the health care system, exposures that tend to result in more frequent contact with the health care system or that are correlated with health care seeking behavior are likely to exhibit differential misclassification. Previously, we found that differential misclassification induced notable bias in effect estimates in the setting of second breast cancers. 14, 16 On the basis of our results, type I error rates for naïve analyses of such exposures will also be substantially inflated.
This study has several strengths. Notably, we used real EHRderived data on second breast cancers including a previously validated EHR-based outcome measure and a chart review-validated gold-standard outcome to inform our simulations. A simulation approach is ideal for characterizing type I error because it provides a setting in which we know, by design, that the gold-standard outcome and exposure are not associated. Any observed association is therefore certain to be spurious. By coupling simulated exposure data with real EHR data,
we are able to ensure that all other elements of the data distribution are realistic and reflect a real-world setting.
Limitations of our study include use of data from a single health care system and disease setting. However, our results in terms of differential misclassification and the magnitude of induced type I error are likely generalizable to other settings. Type I error is sample size dependent. Therefore, our results based on a cohort of approximately 3000 patients represent a lower bound on the inflation of type I rates relative to larger studies. Additionally, while this work highlights the sensitivity of type I error rates to differential misclassification, we have not investigated the ability of statistical approaches for misclassification to correct this type I error inflation.
In conclusion, we found that differential misclassification in EHRderived outcomes can lead to substantially inflated type I error rates and, consequently, false-positive findings. Our investigation highlights FIGURE 1 Color coded contour plot of type I error as a function of sensitivity and specificity in exposed individuals (A), plot of type I error rate versus sensitivity in the exposed (B), and plot of type I error rate versus specificity in the exposed (C), using outcome and covariate data from BRAVA with simulated exposure data. In the contour plot (A), the black dot indicates sensitivity and specificity in the unexposed group. In the sensitivity plot (B), specificity in the exposed group is fixed at the value for the unexposed group (0.9), and in the specificity plot (C), sensitivity in the exposed group is fixed at the value for the unexposed group (0.85) [Colour figure can be viewed at wileyonlinelibrary.com] the importance of using validated outcomes with good operating characteristics, conducting appropriate sensitivity analyses, and using misclassification-adjusted analytic approaches to reduce the risk of identifying spurious relationships.
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